Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NXGL

Nexgel Inc

Feb 06 • 04:00PM ET

1.27

+0.06 4.96 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: TMO MTD SYK BDX ZBH BAX ISRG STE HOLX RMD

| Held by: VXF VTI DCOR DFAC DFAS

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	16.23%	Shs Outstand	8.14M	Perf Week	-10.56%
Market Cap	13.62M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-2.12%	Shs Float	6.82M	Perf Month	-26.16%
Enterprise Value	15.34M	PEG	-	EPS next Q	-0.09	Inst Own	6.89%	Short Float	0.13%	Perf Quarter	-46.41%
Income	-2.88M	P/S	1.17	EPS this Y	30.00%	Inst Trans	-6.54%	Short Ratio	0.13	Perf Half Y	-51.89%
Sales	11.66M	P/B	1.99	EPS next Y	82.86%	ROA	-25.96%	Short Interest	0.01M	Perf YTD	-21.12%
Book/sh	0.64	P/C	7.32	EPS next 5Y	-	ROE	-58.34%	52W High	3.66 -65.30%	Perf Year	-63.82%
Cash/sh	0.17	P/FCF	-	EPS past 3/5Y	13.31% -28.88%	ROIC	-36.35%	52W Low	1.18 7.63%	Perf 3Y	-9.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	77.60% 64.69%	Gross Margin	36.83%	Volatility	7.80% 6.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.32	EPS Y/Y TTM	34.87%	Oper. Margin	-25.54%	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.08	Sales Y/Y TTM	73.38%	Profit Margin	-24.69%	RSI (14)	34.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.69	EPS Q/Q	22.37%	SMA20	-16.42%	Beta	0.63	Target Price	6.00
Payout	-	Debt/Eq	0.61	Sales Q/Q	-0.20%	SMA50	-20.61%	Rel Volume	0.22	Prev Close	1.21
Employees	19	LT Debt/Eq	0.53	Earnings	Nov 11 AMC	SMA200	-42.62%	Avg Volume	68.14K	Price	1.27
IPO	Dec 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -7.27%	Trades		Volume	14,681	Change	4.96%

Dec-16-25 08:00AM	NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor (GlobeNewswire)
Dec-11-25 08:00AM	NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx (GlobeNewswire) +22.67%
Nov-12-25 12:00AM	NexGel Inc (NXGL) Q3 2025 Earnings Call Highlights: Progress Towards Profitability Amidst ... (GuruFocus.com) -11.40%
Nov-11-25 04:10PM	NEXGEL Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 08:00AM	NEXGEL to Report Third Quarter 2025 Financial Results on November 11th (GlobeNewswire)
08:00AM	Loading…
Oct-09-25 08:00AM	NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21 (GlobeNewswire)
Aug-13-25 03:14AM	NexGel Inc (NXGL) Q2 2025 Earnings Call Highlights: Revenue Doubles Amid Strategic Growth and ... (GuruFocus.com) -11.44%
Aug-12-25 04:05PM	NEXGEL Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 08:00AM	NEXGEL to Report Second Quarter 2025 Financial Results on August 12th (GlobeNewswire) -6.96%
Aug-05-25 08:00AM	NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors (GlobeNewswire) +5.00%
Aug-01-25 08:00AM	NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +14.23%
Jul-14-25 09:00AM	NEXGEL and STADA AG Announce Expansion of Partnership for North America (GlobeNewswire) -5.20%
May-21-25 09:00AM	NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd (GlobeNewswire) -5.13%
May-13-25 04:05PM	NEXGEL Reports First Quarter 2025 Financial Results (GlobeNewswire) -9.15%
May-09-25 09:00AM	NEXGEL to Report First Quarter 2025 Financial Results on May 13th (GlobeNewswire)
09:00AM	Loading…
Apr-07-25 09:00AM	NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th (GlobeNewswire)
Mar-24-25 05:41PM	NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript (SeekingAlpha) +14.44%
04:05PM	NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE)
Mar-19-25 09:00AM	NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th (GlobeNewswire)
Mar-13-25 09:00AM	NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 25-26th, 2025 (GlobeNewswire) -7.95%
Feb-13-25 09:00AM	NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025 (GlobeNewswire) +5.64%
Jan-22-25 09:00AM	NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025 (GlobeNewswire)
Jan-02-25 09:00AM	NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer (GlobeNewswire) -14.14%
Dec-06-24 08:30AM	iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 (ACCESS Newswire)
Nov-21-24 09:00AM	NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024 (GlobeNewswire)
Nov-13-24 04:40PM	NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially (GlobeNewswire)
Nov-11-24 05:35PM	NEXGEL Announces $2,000,000 Registered Direct Offering (GlobeNewswire) +8.02% -10.00%
09:00AM	NEXGEL to Report Third Quarter 2024 Financial Results on November 13th (GlobeNewswire)
Oct-11-24 09:05AM	NexGel expects Q3 revenue approx $2.85M (TipRanks)
09:00AM	Loading…
09:00AM	NEXGEL to Participate in Upcoming October Investor Conferences (GlobeNewswire)
Oct-10-24 09:00AM	NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially (GlobeNewswire) +18.75%
Oct-04-24 09:00AM	NEXGEL Appoints Kip Crecca to its Scientific Advisory Board (GlobeNewswire)
Sep-18-24 09:00AM	NEXGEL's Beauty Brand, Silly George, Partners with Multi-Talented Artist and Entrepreneur, James Maslow, to Promote Innovative Eyelash Collection (GlobeNewswire)
Aug-14-24 04:25PM	NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million (GlobeNewswire) -5.61%
Aug-12-24 09:15AM	NEXGEL to Report Second Quarter 2024 Financial Results on August 14th (GlobeNewswire)
09:00AM	NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders (GlobeNewswire)
Jul-18-24 09:15AM	NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal (GlobeNewswire)
Jul-08-24 04:05PM	NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively (GlobeNewswire) -7.69% +9.31%
Jun-27-24 09:00AM	NEXGEL Subsidiary, CG Converting and Packaging, Announces it will Supply SilverSeal to Cintas Corporation (GlobeNewswire)
Jun-11-24 08:40AM	NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America (GlobeNewswire)
May-16-24 09:00AM	NEXGEL Acquires International Beauty Brand, Silly George (GlobeNewswire)
May-13-24 08:53PM	NXGL Stock Earnings: NexGel Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year (GlobeNewswire)
May-09-24 08:00AM	NEXGEL to Report First Quarter 2024 Financial Results on May 13th (GlobeNewswire)
May-06-24 04:05PM	NEXGEL to Present at the Aegis Capital Virtual Conference on May 9, 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-18-24 08:00AM	NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024 (GlobeNewswire)
Apr-02-24 10:28AM	NEXGEL, Inc. (NASDAQ:NXGL) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.25%
Apr-01-24 12:52PM	NXGL Stock Earnings: NexGel Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -17.95%
07:50AM	NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year (GlobeNewswire)
Mar-27-24 09:00AM	NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday (GlobeNewswire)
Mar-21-24 09:00AM	NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th (GlobeNewswire)
Mar-11-24 11:00AM	RETRANSMISSION: iAccess Alpha's Buyside Best Ideas Spring Virtual Conference March 12th and 13th, 2024 (ACCESSWIRE)
Mar-04-24 08:30AM	NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th (GlobeNewswire) +15.53%
Feb-21-24 04:05PM	NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders (GlobeNewswire) +16.83%
Jan-18-24 09:00AM	NEXGEL to Present at The Microcap Conference, January 30th through February 1st (GlobeNewswire)
Jan-09-24 08:30AM	NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 (GlobeNewswire)
Dec-11-23 08:00AM	NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America (GlobeNewswire) +7.87%
Dec-05-23 08:00AM	NEXGEL Acquires Kenkoderm Psoriasis Skincare Line (GlobeNewswire)
Nov-20-23 10:00AM	NEXGEL, Inc. (NASDAQ:NXGL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-16-23 06:35AM	3 Stocks Youll Regret Not Buying Soon: November 2023 (InvestorPlace)
Nov-13-23 04:05PM	NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year (GlobeNewswire)
Nov-02-23 09:00AM	NEXGEL to Report Third Quarter 2023 Financial Results on November 13th (GlobeNewswire)
Oct-30-23 08:00AM	NEXGEL Secures Supply Agreement with AbbVie (GlobeNewswire)
Sep-26-23 09:49AM	NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd (GlobeNewswire)
Sep-15-23 11:02AM	Director Scott Henry Acquires 10,500 Shares of NexGel Inc (GuruFocus.com) -8.89%
Aug-14-23 04:05PM	NEXGEL Reports Second Quarter 2023 Record Revenue of $1.17 Million, an Increase of 108% Year-Over-Year (GlobeNewswire) -5.91%
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research) -11.22%
Aug-09-23 06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research) -12.13%
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research) +8.14%
Aug-02-23 09:00AM	NEXGEL to Report Second Quarter 2023 Financial Results on August 14th (GlobeNewswire) -6.36%
07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research)
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research) +14.08%
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research) -7.02%
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research) +6.54%
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research) -5.78%
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
Jul-19-23 09:10AM	NEXGEL Partners with Enigma Health to Distribute its Leading Products in Retail Stores throughout North America (GlobeNewswire)
07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research)
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research)
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research)
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research)
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research)
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research)
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research)
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research)
Jun-28-23 06:58AM	Daily Vickers Top Insider Picks for 06/28/2023 (Argus Research)

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It operates through the NexGel and CGN segments. The NexGel segment consists of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. The CGN segment consists of the CGN JV used for the company's converting and packaging business, which is based in Granbury, Texas. The company was founded on January 13, 2009, and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levy Adam R.	Chief Executive Officer	Dec 22 '25	Sale	1.61	6,000	9,661	361,692	Dec 29 08:47 AM
Levy Adam R.	Chief Executive Officer	Dec 24 '25	Sale	1.57	4,000	6,286	357,692	Dec 29 08:47 AM
Levy Adam R.	Officer	Dec 22 '25	Proposed Sale	1.64	10,000	16,400		Dec 22 11:24 AM
Levy Adam R.	Chief Executive Officer	Nov 06 '25	Sale	2.52	4,000	10,084	367,692	Nov 07 08:00 PM
Henry Scott Robert	Director	Oct 03 '25	Sale	2.55	7,175	18,298	113,356	Oct 06 08:00 PM
Henry Scott Robert	Director	Oct 02 '25	Sale	2.50	825	2,062	120,531	Oct 06 08:00 PM
Levy Adam R.	Chief Executive Officer	Oct 03 '25	Sale	2.55	2,400	6,119	371,692	Oct 06 08:00 PM
Levy Adam R.	Chief Executive Officer	Oct 02 '25	Sale	2.50	1,600	4,000	374,092	Oct 06 08:00 PM
Levy Adam R.	Officer	Oct 02 '25	Proposed Sale	2.50	16,000	40,000		Oct 02 04:57 PM
Henry Scott Robert	Director	Sep 25 '25	Sale	2.36	7,697	18,149	121,356	Sep 29 08:00 PM
Henry Scott Robert	Director	Sep 25 '25	Proposed Sale	3.05	35,515	108,451		Sep 25 11:55 AM
Levy Adam R.	Chief Executive Officer	Aug 28 '25	Sale	2.47	4,000	9,896	358,284	Aug 29 08:00 PM
Levy Adam R.	Officer	Aug 28 '25	Proposed Sale	2.45	4,000	9,800		Aug 28 01:54 PM
Henry Scott Robert	Director	Jun 13 '25	Sale	2.57	3,000	7,704	129,053	Jun 16 08:00 PM
Levy Adam R.	Chief Executive Officer	Jun 11 '25	Sale	2.39	2,000	4,780	362,284	Jun 11 08:00 PM
Levy Adam R.	Chief Executive Officer	Jun 09 '25	Sale	2.33	2,000	4,659	364,284	Jun 11 08:00 PM
Levy Adam R.	Chief Executive Officer	Jun 05 '25	Sale	2.32	1,000	2,323	366,284	Jun 06 08:00 PM
Levy Adam R.	Chief Executive Officer	Jun 04 '25	Sale	2.29	1,000	2,290	367,284	Jun 06 08:00 PM
Levy Adam R.	Chief Executive Officer	May 30 '25	Sale	2.22	1,000	2,220	368,284	Jun 02 08:00 PM
Levy Adam R.	Chief Executive Officer	May 16 '25	Sale	2.58	1,000	2,575	369,284	May 20 08:00 PM
Levy Adam R.	Officer	May 16 '25	Proposed Sale	2.37	8,000	18,960		May 16 10:41 AM
Henry Scott Robert	Director	May 12 '25	Sale	2.69	3,000	8,062	132,053	May 13 08:00 PM
Henry Scott Robert	Director	Apr 10 '25	Sale	2.61	3,000	7,825	135,053	Apr 14 05:00 PM
Henry Scott Robert	Director	Apr 10 '25	Proposed Sale	2.60	9,000	23,400		Apr 10 10:37 AM
Levy Adam R.	Chief Executive Officer	Apr 01 '25	Sale	3.01	4,000	12,038	370,284	Apr 02 05:00 PM
Henry Scott Robert	Director	Mar 10 '25	Sale	2.87	3,000	8,621	138,053	Mar 11 05:00 PM
Levy Adam R.	Chief Executive Officer	Mar 03 '25	Sale	3.16	4,000	12,639	374,284	Mar 05 05:00 PM
Henry Scott Robert	Director	Feb 10 '25	Sale	3.27	3,000	9,798	138,553	Feb 12 05:00 PM

Open in Screener

PTCT

PTC Therapeutics Inc

Feb 06 • 04:00PM ET

74.68

+2.32 3.21 %

Healthcare • Biotechnology • USA • NASD

PTCT PTC Therapeutics Inc daily Stock Chart

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: IJR VTI VB IWM XBI VBK VXF SPSM IJT IBB

Index	RUT	P/E	8.73	EPS (ttm)	8.56	Insider Own	4.10%	Shs Outstand	79.93M	Perf Week	-1.13%
Market Cap	6.00B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-14.25%	Shs Float	76.99M	Perf Month	-3.31%
Enterprise Value	4.72B	PEG	-	EPS next Q	0.10	Inst Own	105.42%	Short Float	13.37%	Perf Quarter	4.05%
Income	751.72M	P/S	3.37	EPS this Y	303.69%	Inst Trans	12.65%	Short Ratio	6.41	Perf Half Y	48.29%
Sales	1.78B	P/B	-	EPS next Y	-111.11%	ROA	33.51%	Short Interest	10.29M	Perf YTD	-1.69%
Book/sh	-1.95	P/C	3.55	EPS next 5Y	-	ROE	-	52W High	87.50 -14.65%	Perf Year	49.39%
Cash/sh	21.02	P/FCF	8.50	EPS past 3/5Y	14.01% -2.04%	ROIC	-	52W Low	35.95 107.73%	Perf 3Y	57.65%
Dividend Est.	-	EV/EBITDA	4.94	Sales past 3/5Y	14.42% 21.32%	Gross Margin	95.78%	Volatility	4.10% 4.53%	Perf 5Y	31.50%
Dividend TTM	-	EV/Sales	2.65	EPS Y/Y TTM	261.84%	Oper. Margin	51.84%	ATR (14)	3.04	Perf 10Y	224.27%
Dividend Ex-Date	-	Quick Ratio	2.26	Sales Y/Y TTM	97.54%	Profit Margin	42.25%	RSI (14)	47.57	Recom	1.93
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	114.06%	SMA20	-0.82%	Beta	0.50	Target Price	88.50
Payout	-	Debt/Eq	-	Sales Q/Q	7.23%	SMA50	-2.57%	Rel Volume	0.65	Prev Close	72.36
Employees	939	LT Debt/Eq	-	Earnings	Feb 19 AMC	SMA200	23.01%	Avg Volume	1.60M	Price	74.68
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.65% 22.04%	Trades		Volume	1,039,046	Change	3.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$119
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$91
Oct-20-25	Initiated	Wells Fargo	Overweight	$73
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28

Show Previous Ratings

Feb-05-26 08:00AM	PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 (PR Newswire)
Jan-27-26 08:21AM	Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-22-26 03:22AM	Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves (Insider Monkey)
Jan-12-26 08:30AM	PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference (PR Newswire)
04:30PM	Loading…
Jan-08-26 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-22-25 07:00AM	PTC Therapeutics Announces Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan (PR Newswire)
Dec-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.34%
Dec-18-25 08:00AM	PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.90%
09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 06:06PM	SanDisk stock surges after S&P 500 inclusion announcement (Investing.com)
06:01PM	Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Nov-20-25 08:00AM	PTC Therapeutics to Host R&D Day (PR Newswire)
Nov-05-25 12:02AM	PTC Therapeutics Inc (PTCT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.98%
06:00PM	Loading…
Nov-04-25 06:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks)
04:21PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 07:24AM	What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Oct-30-25 05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 12:24PM	Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 (Insider Monkey)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-21-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results (PR Newswire)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
Oct-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-25 11:15AM	PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU (Insider Monkey)
08:35AM	Loading…
Sep-05-25 08:35AM	Here's Why Shares in PTC Therapeutics Soared This Week (Motley Fool)
Sep-03-25 02:03PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily) +5.95%
Aug-29-25 04:52AM	PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich's Ataxia (Insider Monkey)
Aug-21-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
10:35AM	PTC Therapeutics CRL expected, focus moves to Sephience, says RBC Capital (TipRanks)
Aug-19-25 08:00AM	PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA (PR Newswire)
07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-07-25 06:00PM	PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.89%
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
08:00AM	Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE (sepiapterin) (PR Newswire)
Jul-28-25 04:19PM	PTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire) +11.16%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-21-25 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results (PR Newswire)
Jul-09-25 09:36AM	Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '26	Sale	76.45	1,034	79,049	72,693	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 08 '26	Sale	76.50	4,602	352,057	82,887	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 09 '26	Sale	77.41	1,722	133,300	81,165	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 12 '26	Sale	78.70	1,024	80,589	80,141	Jan 12 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '26	Sale	76.45	2,514	192,195	394,453	Jan 12 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '26	Sale	76.45	866	66,206	92,428	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '26	Sale	76.56	4,033	308,760	113,626	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 09 '26	Sale	77.93	2,314	180,320	111,312	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	881	67,352	115,196	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	59	4,511	6,791	Jan 12 05:20 PM
Boulding Mark Elliott	Officer	Jan 09 '26	Proposed Sale	77.92	2,314	180,314		Jan 09 04:11 PM
Pauwels Eric	Officer	Jan 09 '26	Proposed Sale	77.89	2,746	213,889		Jan 09 04:09 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 06 '26	Sale	76.95	1,381	106,268	74,962	Jan 08 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '26	Sale	77.45	1,235	95,651	73,727	Jan 08 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jan 06 '26	Sale	76.95	2,139	164,596	90,310	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 06 '26	Sale	76.95	1,789	137,664	88,841	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 07 '26	Sale	77.48	1,352	104,753	87,489	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 06 '26	Sale	76.95	5,149	396,216	399,983	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '26	Sale	77.48	3,016	233,680	396,967	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	76.95	1,340	103,113	93,936	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '26	Sale	77.48	642	49,742	93,294	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Option Exercise	38.10	3,376	128,626	120,284	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Sale	77.44	4,879	377,825	117,659	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 06 '26	Sale	76.95	1,739	133,816	119,162	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	1,279	98,419	117,103	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	1,026	79,494	116,077	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	54	4,155	6,902	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	52	4,029	6,850	Jan 08 05:20 PM
Golden Lee Scott	Officer	Jan 08 '26	Proposed Sale	76.45	866	66,205		Jan 08 04:45 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.53	3,148	240,905		Jan 08 04:37 PM
Klein Matthew B.	Officer	Jan 08 '26	Proposed Sale	76.45	2,514	192,193		Jan 08 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '26	Proposed Sale	76.45	59	4,510		Jan 08 04:29 PM
Almstead Neil Gregory	Officer	Jan 08 '26	Proposed Sale	76.45	881	67,352		Jan 08 04:27 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.45	1,454	111,157		Jan 08 04:24 PM
Utter Christine Marie	Officer	Jan 08 '26	Proposed Sale	76.45	1,034	79,048		Jan 08 04:22 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.45	1,286	98,314		Jan 08 04:17 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.61	2,747	210,448		Jan 08 04:10 PM
Klein Matthew B.	Officer	Jan 07 '26	Proposed Sale	77.48	3,016	233,691		Jan 07 04:38 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.42	3,376	261,382		Jan 07 04:37 PM
Golden Lee Scott	Officer	Jan 07 '26	Proposed Sale	77.48	642	49,745		Jan 07 04:37 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.48	1,503	116,458		Jan 07 04:36 PM
Utter Christine Marie	Officer	Jan 07 '26	Proposed Sale	77.48	1,235	95,692		Jan 07 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '26	Proposed Sale	77.48	52	4,029		Jan 07 04:21 PM
Pauwels Eric	Officer	Jan 07 '26	Proposed Sale	77.48	1,352	104,758		Jan 07 04:17 PM
Almstead Neil Gregory	Officer	Jan 07 '26	Proposed Sale	77.48	1,026	79,498		Jan 07 04:14 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Option Exercise	39.42	2,266	89,326	123,167	Jan 06 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Sale	75.55	2,266	171,192	120,901	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Option Exercise	46.54	734	34,160	11,400	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Sale	76.00	734	55,784	10,666	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Option Exercise	30.86	12,000	370,320	30,500	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Sale	76.35	12,000	916,200	18,500	Jan 06 05:20 PM
Klein Matthew B.	Officer	Jan 06 '26	Proposed Sale	76.95	5,149	396,203		Jan 06 04:46 PM
Utter Christine Marie	Officer	Jan 06 '26	Proposed Sale	76.95	1,381	106,265		Jan 06 04:42 PM
Golden Lee Scott	Officer	Jan 06 '26	Proposed Sale	76.95	1,340	103,110		Jan 06 04:33 PM
Boulding Mark Elliott	Officer	Jan 06 '26	Proposed Sale	76.95	1,739	133,812		Jan 06 04:25 PM
Gravier Pierre	Officer	Jan 06 '26	Proposed Sale	76.95	2,139	164,591		Jan 06 04:25 PM
Almstead Zheng Yang	Member of immediate family of	Jan 06 '26	Proposed Sale	76.95	54	4,155		Jan 06 04:24 PM
Pauwels Eric	Officer	Jan 06 '26	Proposed Sale	76.95	1,789	137,659		Jan 06 04:16 PM
Almstead Neil Gregory	Officer	Jan 06 '26	Proposed Sale	76.95	1,279	98,416		Jan 06 04:15 PM
Boulding Mark Elliott	Officer	Jan 05 '26	Proposed Sale	76.00	2,266	172,216		Jan 05 02:00 PM
Reeve Emma	Director	Jan 05 '26	Proposed Sale	76.00	734	55,784		Jan 05 11:02 AM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 30 '25	Sale	76.64	8,089	619,941	341,875	Jan 02 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Proposed Sale	76.35	12,000	916,200		Jan 02 12:37 PM
Klein Matthew B.	Officer	Dec 30 '25	Proposed Sale	76.64	8,089	619,922		Dec 30 03:09 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Option Exercise	65.15	20,508	1,336,186	90,178	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Sale	77.26	20,508	1,584,350	70,373	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Option Exercise	62.06	40,290	2,500,282	105,734	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Option Exercise	62.69	3,202	200,732	73,204	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Sale	75.43	40,290	3,038,924	70,373	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Sale	75.06	3,202	240,351	70,373	Dec 19 05:20 PM
Pauwels Eric	Officer	Dec 19 '25	Proposed Sale	77.26	20,508	1,584,388		Dec 19 04:18 PM
SCHMERTZLER MICHAEL	Director	Dec 16 '25	Option Exercise	30.86	24,000	740,640	155,266	Dec 18 05:20 PM
Pauwels Eric	Officer	Dec 18 '25	Proposed Sale	75.06	3,202	240,354		Dec 18 04:30 PM
Pauwels Eric	Officer	Dec 17 '25	Proposed Sale	75.42	40,290	3,038,756		Dec 17 04:30 PM
Reeve Emma	Director	Dec 03 '25	Option Exercise	46.54	733	34,114	7,399	Dec 05 05:20 PM
Reeve Emma	Director	Dec 03 '25	Sale	78.62	733	57,628	6,666	Dec 05 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 02 '25	Sale	79.07	3,428	271,052	349,964	Dec 03 05:20 PM
Reeve Emma	Director	Dec 03 '25	Proposed Sale	78.62	733	57,628		Dec 03 10:40 AM
Klein Matthew B.	Officer	Dec 02 '25	Proposed Sale	79.07	3,428	271,063		Dec 02 03:11 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Option Exercise	30.75	71,928	2,211,679	148,249	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Sale	83.44	71,928	6,001,932	100,625	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Option Exercise	30.23	35,572	1,075,296	121,831	Nov 26 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Sale	80.18	35,572	2,852,031	100,625	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Option Exercise	15.00	14,199	213,017	25,351	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Option Exercise	14.73	11,801	173,883	23,551	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Sale	83.55	14,199	1,186,282	17,451	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Sale	80.14	11,801	945,736	17,451	Nov 26 05:20 PM
Reeve Emma	Director	Nov 21 '25	Option Exercise	51.16	10,000	511,600	16,666	Nov 25 05:20 PM
Reeve Emma	Director	Nov 21 '25	Sale	79.50	10,000	795,000	6,666	Nov 25 05:20 PM
Almstead Neil Gregory	Officer	Nov 25 '25	Proposed Sale	83.44	71,928	6,001,523		Nov 25 05:18 PM
Jacobson Allan Steven	Director	Nov 25 '25	Proposed Sale	83.45	14,199	1,184,975		Nov 25 04:23 PM
Almstead Neil Gregory	Officer	Nov 24 '25	Proposed Sale	80.18	35,572	2,852,154		Nov 24 04:34 PM
Jacobson Allan Steven	Director	Nov 24 '25	Proposed Sale	80.14	11,801	945,753		Nov 24 04:29 PM
Reeve Emma	Director	Nov 21 '25	Proposed Sale	79.50	10,000	795,000		Nov 21 04:38 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Option Exercise	25.69	2,812	72,240	106,713	Nov 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Sale	75.99	2,812	213,687	103,901	Nov 19 05:20 PM
Boulding Mark Elliott	Officer	Nov 17 '25	Proposed Sale	75.01	2,812	210,928		Nov 17 10:06 AM
Reeve Emma	Director	Nov 12 '25	Option Exercise	46.54	7,333	341,278	13,999	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Sale	74.50	7,333	546,308	6,666	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Proposed Sale	74.50	7,333	546,308		Nov 12 11:58 AM

NXGL

Nexgel Inc

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience